Drug Trial Radar · NCT04772781
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Jun 3, 2022
Primary completion
May 25, 2023
Study completion May 25, 2023
Sponsor
- Lead sponsor
- Apsen Farmaceutica S.A.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals with at least moderate acute mechanical low back pain.
Conditions
- Low Back Pain, Mechanical
- Low Back Pain
- Acute Low Back Pain
Interventions
S (+) - IbuprofenDrug
S (+) - Ibuprofen + placebo of Ibuflex®
Ibuflex®Drug
Ibuflex® + placebo of S (+) - Ibuprofen
Primary outcomes
What the sponsor says the trial is designed to measure.
- At least 50% of maximum pain relief score in Maximum Total Pain Relief (TOTPARmax)Time frame: Change from Baseline to 6 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Apsen Farmacêutica S.A.
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.